There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bluebird Bio (BLUE) and Nurix Therapeutics (NRIX) with bullish sentiments.
Bluebird Bio (BLUE)
In a report issued on August 5, Cory Kasimov from J.P. Morgan maintained a Buy rating on Bluebird Bio, with a price target of $140.00. The company’s shares closed last Tuesday at $61.85.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.1% and a 55.1% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bluebird Bio with a $105.08 average price target, which is a 69.4% upside from current levels. In a report issued on July 29, Oppenheimer also assigned a Buy rating to the stock with a $111.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
